Opthea Limited (OPT)
| Market Cap | 507.33M |
| Revenue (ttm) | 61,405 |
| Net Income (ttm) | -11.62M |
| Shares Out | 43.14M |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | 6.73 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $11.93 |
| Previous Close | $11.75 |
| Change ($) | 0.18 |
| Change (%) | 1.53% |
| Day's Open | 11.87 |
| Day's Range | 11.91 - 12.35 |
| Day's Volume | 1,411 |
| 52-Week Range | 11.11 - 13.50 |
Nine IPOs and five SPACs went public this past week, and one IPO postponed.
MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent a...
Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies. About Opthea: The main area of focus for Opthea L...
About OPT
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The c... [Read more...]
| Industry Biotechnology | IPO Date Oct 16, 2020 |
| CEO Megan Baldwin | Employees 8 |
| Stock Exchange NASDAQ | Ticker Symbol OPT |
Financial Performance
In 2020, Opthea's revenue was 87,075, a decrease of -45.26% compared to the previous year's 159,064. Losses were -16.53 million, -20.95% less than in 2019.